Xenon Pharmaceuticals Inc.
XENE
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.8B
$60.22
▲ +0.38%
P/E
-12.70
Mkt Cap
$5.8B
52-Wk Range
$35.60–$72.66
52-Week Range
$35.60 - $72.66
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 53.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary ion channel modulation platform with deep expertise in neurological targets
- Advanced clinical pipeline with multiple Phase II/III assets reducing development risk
- Strategic partnerships with established biotech firms (Neurocrine, Flexion) providing validation and resources
- Focus on rare genetic neurological disorders with high unmet medical needs and potential for premium pricing
- Experienced management team with track record in neurological drug development
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
XEN496 Phase III trial progression for KCNQ2-related epilepsy with potential FDA approval pathway
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+12.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying XENE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 6, 2026
Reported EPS of -$1.11 vs -$1.14 consensus (+2.6% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+2.6%
Revenue trend · last 8Q
—
—
—
—
—
—
-100%
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$7.5M
$0
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
8 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 10, 2026
vs Industry
How XENE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related